[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mild-alzheimer39s-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mild-alzheimer39s-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100606678","phase-2-evaluation-of-the-safety-and-efficacy-of-neuroepo-in-subjects-with-mild-to-moderate-alzheimers-disease-100606678",false,"NCT07178678","Evaluation of the Safety and Efficacy of NeuroEPO in Subjects With Mild to Moderate Alzheimer's Disease","A Phase II, Blinded, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of NeuroEPO in Subjects With Mild to Moderate Alzheimer's Disease Who Are Receiving Standard of Care Treatment","Inclusion Criteria:\n\n* Patients \\>= 50 years of age, to reflect the population that will be treated and to avoid younger populations who may be suffering dementia from a cause other than Alzheimer's Disease.\n* Patients with Global Deterioration Scale (GDS) between 3 to 5 points (inclusive).\n* Clinical Dementia Rating (CDR) - GS score 1-2 at screening.\n* Patients with permeable airways.\n* Patients (or caregiver, if the patient cannot) grant consent to participate in the study by signing the informed consent form.\n* Patient with caregiver is physically and mentally willing to collaborate with the investigation.\n* Mini-Mental State Examination (MMSE) score between 14 and 26 (inclusive) at screening\n\nExclusion Criteria:\n\n* Evident mental disability or other limitation that prevents the patient or caregiver from administering the study evaluations.\n* Patients with neurological symptoms or signs that suggest another cause of dementia.\n* Skull trauma or recent intracranial surgery.\n* Known clotting disorders.\n* Use of anticoagulants, a medication to prevent harmful blood clots (warfarin, heparin or NOAC).\n* Patients where coexistence of another disease or condition that may lead to significant disability (cancer, septic embolism, endocarditis, myeloproliferative disease, creatinine\\> 3 mg \u002F dl (265µmol \u002F L), hyperkalemia \\> 5.0 mmol \u002F L, chronic\u002Fsevere liver or kidney or heart disorders.\n* Patients with a history of hypersensitivity to rhEPO.\n* Patients with known allergy to any ingredients of the product.\n* Patients who present nasal irritation (sneezing) or a runny nose before starting treatment.\n* Patients who present asthma attack at the beginning of the treatment.\n* Patients receiving treatment with AChE-I or Memantine who are not stable for 12-weeks prior to screening.\n* Patients receiving treatment with psychoactive that can compromise the clinical trial results or neuropsychological tests.\n* Patients with a history of alcoholism and\u002For drug dependence.\n* Patients with chronic rhinosinusitis.\n* Have a history of abnormal nasal or sinus symptoms.\n* Have prior skull fracture or abnormality (nasal defect, deviated septum).\n* Have recent nasal trauma (fracture in the last 2 months).\n* Have any prior sinus or nose surgery (rhinoplasty).\n* Have known bleeding problem (low platelets-thrombocytopenia), recurrent nose bleeds (\\>3 year).\n* Have acute inflammation inside the nose.\n* Congenital cranial facial disorders.","ALL","50 Years",{"count":19,"type":20},90,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The goal of this clinical trial is to test if NeuroEPO improves or maintains cognition in adults with mild to moderate Alzheimer's Disease using a cannula attached to a syringe for delivery. It will also learn the safety of NeuroEPO. The main questions it aims to answer are:\n\nDoes NeuroEPO lower or maintain a person's cognition who has been diagnosed with Alzheimer's Disease? What medical problems do participants have when taking NeuroEPO?\n\nResearchers will compare NeuroEPO to a placebo (a look-alike substance that contains no drug) to see if NeuroEPO works to treat Alzheimer's Disease.\n\nParticipants will:\n\nTake NeuroEPO or a placebo three times a week for one year Visit the clinic to determine eligibility, for cognitive testing and blood tests at the start and end of the trial and at 1, 2, 6 and 12 months for check ups and blood collection",[26,27],"Mild Alzheimer's Disease","Moderate Alzheimer's Disease",[29,30,31,32],"Alzheimer's Disease","NeuroEPO","EPO","ADAS-cog13","NOT_YET_RECRUITING","2025-09-10",{"date":36,"type":37},"2025-09-17","ACTUAL",{"date":39,"type":20},"2025-11",{"date":41,"type":20},"2030-12",{"name":43,"class":44},"University of Saskatchewan","OTHER"]